Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs

The current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) are the C5 inhibitors eculizumab and ravulizumab, both monoclonal antibodies designed to target the complement protein C5, thereby preventing its cleavage and the formation of the terminal attack complex. C5 inhibitors have y...

Descripción completa

Detalles Bibliográficos
Autores principales: Bektas, Meryem, Copley-Merriman, Catherine, Khan, Shahnaz, Sarda, Sujata P, Shammo, Jamile M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Supplement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410676/
https://www.ncbi.nlm.nih.gov/pubmed/33356783
http://dx.doi.org/10.18553/jmcp.2020.26.12-b.s14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410676/
https://www.ncbi.nlm.nih.gov/pubmed/33356783
http://dx.doi.org/10.18553/jmcp.2020.26.12-b.s14

Ejemplares similares